PMID- 21430370
OWN - NLM
STAT- MEDLINE
DCOM- 20110823
LR  - 20151119
IS  - 1421-9662 (Electronic)
IS  - 0001-5792 (Linking)
VI  - 126
IP  - 1
DP  - 2011
TI  - Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with 
      bendamustine and rituximab.
PG  - 40-3
LID - 10.1159/000324193 [doi]
AB  - Herein, we describe a case of a female patient in whom B cell chronic lymphocytic 
      leukemia (CLL) and mantle cell lymphoma (MCL) were diagnosed simultaneously. She 
      presented with anemia, thrombocytopenia and splenomegaly. Flow cytometry 
      demonstrated two immunophenotypically distinct CD5-positive monoclonal B cell 
      populations. Peripheral blood fluorescence in situ hybridization (FISH) was 
      positive for IGH/CCND1, consistent with t(11;14) translocation. She received 6 
      cycles of bendamustine 70 mg/m(2)/day for 2 days and rituximab on the first day 
      every 4 weeks along with granulocyte-colony stimulating factor. She had an 
      excellent response, and repeat computed tomography after her third cycle of 
      chemotherapy revealed no organomegaly or lymphadenopathy. Her peripheral blood 
      lymphocytosis also resolved. Bone marrow examination revealed no detectable 
      flow-cytometric evidence of MCL or CLL. Repeat cytogenetic and FISH analysis were 
      also normal. The patient remains in complete remission 20 months after her 
      initial diagnosis and is receiving maintenance rituximab 375 mg/m(2) weekly for 4 
      weeks every 6 months for 2 years.
CI  - Copyright (c) 2011 S. Karger AG, Basel.
FAU - Kourelis, Taxiarchis V
AU  - Kourelis TV
AD  - Department of Medicine, Saint Francis Hospital and Medical Center, Hartford, CT 
      06103, USA. taxkourel@yahoo.com
FAU - Kahl, Brad S
AU  - Kahl BS
FAU - Benn, Peter
AU  - Benn P
FAU - Delach, Judith A
AU  - Delach JA
FAU - Bilgrami, Syed F
AU  - Bilgrami SF
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20110323
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Nitrogen Mustard Compounds)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bendamustine Hydrochloride
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/complications/*drug therapy
MH  - Lymphoma, Mantle-Cell/complications/*drug therapy
MH  - Nitrogen Mustard Compounds/administration & dosage
MH  - Rituximab
EDAT- 2011/03/25 06:00
MHDA- 2011/08/24 06:00
CRDT- 2011/03/25 06:00
PHST- 2010/12/13 00:00 [received]
PHST- 2010/12/29 00:00 [accepted]
PHST- 2011/03/25 06:00 [entrez]
PHST- 2011/03/25 06:00 [pubmed]
PHST- 2011/08/24 06:00 [medline]
AID - 000324193 [pii]
AID - 10.1159/000324193 [doi]
PST - ppublish
SO  - Acta Haematol. 2011;126(1):40-3. doi: 10.1159/000324193. Epub 2011 Mar 23.